Abstract:Bone is one of the most prevalent sites of metastases in various epithelial malignancies, including breast cancer and this metastasis to bone often leads to severe skeletal complications in women due to its osteolytic nature. To address this, we devised a novel drug delivery approach using an Alendronate (ALN) functionalized self-assembled porous crystalsomes for concurrent targeting of Oleanolic acid (OA) and ALN (ALN + OA@NCs) to bone metastasis. Initially, the conjugation of both PEG-OA and OA-PEG-ALN with ALN and OA was achieved, and this conjugation was then self-assembled into porous crystalsomes (ALN + OA@NCs) by nanoemulsion crystallization. The reconstruction of a 3D single particle using transmission electron microscopy ensured the crystalline porous structure of ALN + OA@NCs, was well aligned with characteristic nanoparticle attributes including size distribution, polydispersity, and zeta potential. Further, ALN + OA@NCs showed enhanced efficacy in comparison to OA@NCs suggesting the cytotoxic roles of ALN towards cancer cells, followed by augmentation ROS generation (40.81%), mitochondrial membrane depolarization (57.20%), and induction of apoptosis (40.43%). We found that ALN + OA@NCs facilitated inhibiting osteoclastogenesis and bone resorption followed by inhibited osteolysis. In vivo activity of ALN + OA@NCs in the 4 T1 cell-induced tibia model rendered a reduced bone loss in the treated mice followed by restoring bone morphometric markers which were further corroborated bone-targeting effects of ALN + OA@NCs to reduce RANKL-stimulated osteoclastogenesis. Further, In vivo intravenous pharmacokinetics showed the improved therapeutic profile of the ALN + OA@NCs in comparison to the free drug, prolonging the levels of the drug in the systemic compartment by reducing the clearance culminating the higher accumulation at the tumor site. Our finding proposed that ALN + OA@NCs can effectively target and treat breast cancer metastasis to bone and its associated complications.

Bone-targeted PAMAM micelle to treat bone metastases of lung cancer

Osteoclasts and Tumor Cells Dual Targeting Nanoparticle to Treat Bone Metastases of Lung Cancer

Bone metastasis target redox-responsive micell for the treatment of lung cancer bone metastasis and anti-bone resorption.

Doxorubicin-Poly (ethylene Glycol)-Alendronate Self-Assembled Micelles for Targeted Therapy of Bone Metastatic Cancer

Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment

Actively Targeted Delivery of Doxorubicin to Bone Metastases by a Ph-Sensitive Conjugation

Bortezomib-catechol Conjugated Prodrug Micelles: Combining Bone Targeting and Aryl Boronate-Based Ph-Responsive Drug Release for Cancer Bone-Metastasis Therapy

Alendronate-functionalized hypoxia-responsive polymeric micelles for targeted therapy of bone metastatic prostate cancer

Inhibition of Metastatic Bone Cancer with a Cascade Targeting of Docetaxel

Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone.

Dendrimer-based micelles with highly potent targeting to sites of active bone turnover for the treatment of bone metastasis

Multifunctional melanin-like nanoparticles for bone-targeted chemo-photothermal therapy of malignant bone tumors and osteolysis

Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis

DOX-loaded Mesoporous Hydroxyapatite Modified by Hyaluronic Acid Can Achieve Efficient Targeted Therapy for Lung Cancer.

Redox and Ph Dual Sensitive Bone Targeting Nanoparticles to Treat Breast Cancer Bone Metastases and Inhibit Bone Resorption.

Bone-Targeted Calcium Phosphate-Polymer Hybrid Nanoparticle Co-Deliver Zoledronate and Docetaxel to Treat Bone Metastasis of Prostate Cancer

Development of a bone targeted thermosensitive liposomal doxorubicin formulation based on a bisphosphonate modified non-ionic surfactant

Alendronate-functionalized porous nano-crystalsomes mitigate osteolysis and consequent inhibition of tumor growth in a tibia-induced metastasis model

Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy

Pamidronate Functionalized Nanoconjugates for Targeted Therapy of Focal Skeletal Malignant Osteolysis

Preparation and in Vitro Evaluation of Doxorubicin Loaded Alendronate Modified Hollow Gold Nanoparticles for Bone -Targeted Chemo-Photothermal Therapy